Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Corvus Pharmaceuticals (CRVS) Current Leases (2022 - 2025)

Historic Current Leases for Corvus Pharmaceuticals (CRVS) over the last 4 years, with Q3 2025 value amounting to $379000.0.

  • Corvus Pharmaceuticals' Current Leases rose 706.21% to $379000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $379000.0, marking a year-over-year increase of 706.21%. This contributed to the annual value of $185000.0 for FY2024, which is 8653.57% down from last year.
  • Corvus Pharmaceuticals' Current Leases amounted to $379000.0 in Q3 2025, which was up 706.21% from $355000.0 recorded in Q2 2025.
  • Over the past 5 years, Corvus Pharmaceuticals' Current Leases peaked at $1.4 million during Q4 2023, and registered a low of $185000.0 during Q4 2024.
  • Over the past 4 years, Corvus Pharmaceuticals' median Current Leases value was $1.1 million (recorded in 2022), while the average stood at $882533.3.
  • As far as peak fluctuations go, Corvus Pharmaceuticals' Current Leases surged by 1587.16% in 2023, and later tumbled by 8653.57% in 2024.
  • Corvus Pharmaceuticals' Current Leases (Quarter) stood at $1.2 million in 2022, then increased by 11.89% to $1.4 million in 2023, then plummeted by 86.54% to $185000.0 in 2024, then soared by 104.86% to $379000.0 in 2025.
  • Its last three reported values are $379000.0 in Q3 2025, $355000.0 for Q2 2025, and $319000.0 during Q1 2025.